- Home
- XFOR vs ZNTL Comparison
XFOR vs ZNTL Comparison
Compare XFOR & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- ZNTL
- Stock Information
- Founded
- XFOR 2014
- ZNTL 2014
- Country
- XFOR United States
- ZNTL United States
- Employees
- XFOR N/A
- ZNTL N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- XFOR Health Care
- ZNTL Health Care
- Exchange
- XFOR Nasdaq
- ZNTL Nasdaq
- Market Cap
- XFOR 118.4M
- ZNTL 102.2M
- IPO Year
- XFOR N/A
- ZNTL 2020
- Fundamental
- Price
- XFOR $3.40
- ZNTL $1.21
- Analyst Decision
- XFOR Strong Buy
- ZNTL Buy
- Analyst Count
- XFOR 3
- ZNTL 9
- Target Price
- XFOR $72.33
- ZNTL $8.69
- AVG Volume (30 Days)
- XFOR 180.2K
- ZNTL 689.9K
- Earning Date
- XFOR 05-01-2025
- ZNTL 05-14-2025
- Dividend Yield
- XFOR N/A
- ZNTL N/A
- EPS Growth
- XFOR N/A
- ZNTL N/A
- EPS
- XFOR 2.16
- ZNTL N/A
- Revenue
- XFOR $31,364,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- XFOR $915.88
- ZNTL N/A
- Revenue Next Year
- XFOR N/A
- ZNTL N/A
- P/E Ratio
- XFOR $1.57
- ZNTL N/A
- Revenue Growth
- XFOR N/A
- ZNTL N/A
- 52 Week Low
- XFOR $2.67
- ZNTL $1.01
- 52 Week High
- XFOR $33.90
- ZNTL $13.00
- Technical
- Relative Strength Index (RSI)
- XFOR 39.83
- ZNTL 42.23
- Support Level
- XFOR $2.67
- ZNTL $1.18
- Resistance Level
- XFOR $3.56
- ZNTL $1.27
- Average True Range (ATR)
- XFOR 0.28
- ZNTL 0.07
- MACD
- XFOR 0.21
- ZNTL 0.01
- Stochastic Oscillator
- XFOR 82.02
- ZNTL 30.30
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.